Cereton, 400mg capsules, 14pcs

Composition

1 capsule contains:

Active ingredient:

choline alfoscerate (based on 100% substance) 400 mg;

excipients:

glycerol;

purified water;

capsule composition:

gelatin; sorbitol; glycerol; methyl parahydroxybenzoate; propyl parahydroxybenzoate; titanium dioxide; iron oxide yellow dye; purified water

Pharmacological action

Pharmaceutical group:

nootropic agent.

Pharmaceutical action:

Cereton is a nootropic agent. Central cholinostimulator, which contains 40.5% of metabolically protected choline. Metabolic protection promotes the release of choline in the brain.

Provides synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. Increases the linear velocity of blood flow on the side of traumatic brain injury, contributes to the normalization of spatiotemporal characteristics of spontaneous bioelectric activity of the brain, regression of focal neurological symptoms and restoration of consciousness; has a positive effect on the cognitive and behavioral responses of patients with vascular diseases of the brain (dyscirculatory encephalopathy and residual phenomena of cerebral circulatory disorders).

It has a preventive and corrective effect on the pathogenetic factors of involutional psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity.

It stimulates the dose-dependent release of acetylcholine under physiological conditions; by participating in the synthesis of phosphatidylcholine (a membrane phospholipid), it improves synaptic transmission, plasticity of neuronal membranes, and receptor function. It does not affect the reproductive cycle and has no teratogenic, mutagenic effect.

Pharmacokinetics:

 When taken parenterally (10 mg/kg), Cereton® mainly accumulates in the brain, lungs and liver. Absorption – 88%, easily penetrates the blood-brain barrier (when taken orally, the concentration in the brain is 45% of that in plasma).

85% of the drug is excreted by the lungs in the form of carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

Indications

• acute (solution for injection) and recovery periods of severe head injury and ischemic stroke, the recovery period of hemorrhagic stroke, occurring with a focal hemispheric symptoms or symptoms of lesions of the brain stem;
• psycho-organic syndrome on the background of involution and degenerative changes in the brain;
• cognitive disorders (disorders of mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to focus), including dementia and encephalopathy;
• senile pseudomalachite.

Use during pregnancy and lactation

The use of the drug Tsereton during pregnancy and lactation is contraindicated.

Breast-feeding should be discontinued during treatment with Cereton.

Contraindications

• hypersensitivity to the drug;
• acute stage of hemorrhagic stroke;
• pregnancy; breast-feeding period;
• children under 18 years of age (due to lack of data).

Side effects

Nausea may occur (mainly as a result of dopaminergic activation), in this case, the dose of the drug is reduced.

Allergic reactions.

Solution for injection

From the digestive system: constipation, diarrhea, dryness of the oral mucosa, pharyngitis.

Nervous system disorders: headache, drowsiness, insomnia, aggressiveness, anxiety, nervousness, cerebral ischemia, convulsions, dizziness.

Skin disorders: rash, urticaria.

Other: pain at the injection site, increased urination.

How to take, course of use and dosage

In the recovery period of traumatic brain injury, ischemic or hemorrhagic stroke, Cereton in the form of capsules is prescribed 800 mg in the morning and 400 mg in the afternoon for 6 months.

In patients with chronic cerebrovascular insufficiency and dementia syndromes, Tsereton is prescribed 400 mg (1 capsule) 3 times a day, preferably after meals, for 3-6 months.

Overdose

Nausea may occur. Treatment: symptomatic therapy.

Special instructions

Ceretone does not affect the speed of psychomotor reactions.

Form of production

Capsules

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Choline alfoscerate

Conditions of release from pharmacies

By prescription

Dosage form

Capsules

Description

For adults as directed by your doctor

Indications

Acquired Dementia, Impaired Cerebral Circulation, Stroke Effects, Alzheimer ‘s Disease